258 related articles for article (PubMed ID: 11129129)
21. [Treatment of diabetes in metabolic syndrome].
Pelikánova T
Vnitr Lek; 2009; 55(7-8):637-45. PubMed ID: 19731868
[TBL] [Abstract][Full Text] [Related]
22. [Intensified treatment of type 2 diabetes mellitus. Is polypharmacy necessary and justified?].
Pedersen OB; Gaede PH
Ugeskr Laeger; 2000 Jun; 162(25):3582-91. PubMed ID: 11016281
[TBL] [Abstract][Full Text] [Related]
23. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial.
Ikramuddin S; Korner J; Lee WJ; Connett JE; Inabnet WB; Billington CJ; Thomas AJ; Leslie DB; Chong K; Jeffery RW; Ahmed L; Vella A; Chuang LM; Bessler M; Sarr MG; Swain JM; Laqua P; Jensen MD; Bantle JP
JAMA; 2013 Jun; 309(21):2240-9. PubMed ID: 23736733
[TBL] [Abstract][Full Text] [Related]
24. Type 2 diabetes care: the role of insulin-sensitizing agents and practical implications for cardiovascular disease prevention.
Henry RR
Am J Med; 1998 Jul; 105(1A):20S-26S. PubMed ID: 9707264
[TBL] [Abstract][Full Text] [Related]
25. Metformin and vascular protection: a cardiologist's view.
Libby P
Diabetes Metab; 2003 Sep; 29(4 Pt 2):6S117-20. PubMed ID: 14502109
[TBL] [Abstract][Full Text] [Related]
26. Multifactorial aspects of the treatment of the type II diabetic patient.
Colwell JA
Metabolism; 1997 Dec; 46(12 Suppl 1):1-4. PubMed ID: 9439550
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
Cavender MA; Lincoff AM
Am J Cardiovasc Drugs; 2010; 10(4):209-16. PubMed ID: 20653327
[TBL] [Abstract][Full Text] [Related]
28. [Prevention of cardiovascular disease in type 2 diabetic patients].
Yokota C
Nihon Rinsho; 2003 Jul; 61(7):1161-6. PubMed ID: 12877078
[TBL] [Abstract][Full Text] [Related]
29. Addressing the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome in the southeastern United States, part II: treatment recommendations for management of the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome.
Bestermann W; Houston MC; Basile J; Egan B; Ferrario CM; Lackland D; Hawkins RG; Reed J; Rogers P; Wise D; Moore MA
Am J Med Sci; 2005 Jun; 329(6):292-305. PubMed ID: 15958871
[TBL] [Abstract][Full Text] [Related]
30. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
[TBL] [Abstract][Full Text] [Related]
31. Regarding "Pharmacologic risk factor management in peripheral arterial disease: a vade mecum for vascular surgeons".
Paraskevas KI
J Vasc Surg; 2008 Sep; 48(3):776-7; author reply 777. PubMed ID: 18727983
[No Abstract] [Full Text] [Related]
32. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
[TBL] [Abstract][Full Text] [Related]
33. Diabetes mellitus: a cardiovascular disease.
Candido R; Srivastava P; Cooper ME; Burrell LM
Curr Opin Investig Drugs; 2003 Sep; 4(9):1088-94. PubMed ID: 14582453
[TBL] [Abstract][Full Text] [Related]
34. Type 2 diabetes mellitus: prevention of macrovascular complications.
Meeuwisse-Pasterkamp SH; van der Klauw MM; Wolffenbuttel BH
Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):323-41. PubMed ID: 18327994
[TBL] [Abstract][Full Text] [Related]
35. [A search for novel pathways of effective prevention of cardiovascular complications in patients with type 2 diabetes mellitus: advance trial].
Karpov IuA; Shubina AT
Kardiologiia; 2007; 47(10):90-5. PubMed ID: 18260953
[No Abstract] [Full Text] [Related]
36. Treating diabetes: cardiovascular benefits of antidiabetes drugs.
Harmel AP
Am J Manag Care; 2002 May; 8(8 Suppl):S219-28; quiz S229-32. PubMed ID: 12022237
[TBL] [Abstract][Full Text] [Related]
37. The UKPDS: implications for the dyslipidaemic patient.
Holman R
Acta Diabetol; 2001; 38 Suppl 1():S9-14. PubMed ID: 11829452
[TBL] [Abstract][Full Text] [Related]
38. Diabetes and heart disease an evidence-driven guide to risk factors management in diabetes.
Lteif AA; Mather KJ; Clark CM
Cardiol Rev; 2003; 11(5):262-74. PubMed ID: 12943604
[TBL] [Abstract][Full Text] [Related]
39. Strategies for the management of diabetic dyslipidaemia.
Taskinen MR
Drugs; 1999; 58 Suppl 1():47-51; discussion 75-82. PubMed ID: 10576525
[TBL] [Abstract][Full Text] [Related]
40. Prevention of macrovascular disease in patients with diabetes mellitus: opportunities for intervention.
Mazzone T
Am J Med; 2007 Sep; 120(9 Suppl 2):S26-32. PubMed ID: 17826043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
